We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

5 hedge funds and large institutions have $367K invested in Scinai Immunotherapeutics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more capital invested

Capital invested by funds: $102K → $367K (+$265K)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

67% more funds holding

Funds holding: 3 → 5 (+2)

0.18% more ownership

Funds ownership: 0.21% → 0.39% (+0.18%)

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$160K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$72.1K
3
Deutsche Bank
Deutsche Bank
Germany
+$5.15K

Top Sellers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$44K

SCNI Hedge Fund Activity: Q1 2017 in Review

5 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2017, worth a combined $367K — up 260% from $102K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new SCNI positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $160K. The largest seller was Bank of Montreal, exiting entirely with an estimated $44K sold.

  • 5 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2017, up from 3 in Q4 2016.
  • Funds reported $367K of Scinai Immunotherapeutics stock for Q1 2017, up 260% quarter-over-quarter.
  • 3 funds opened new Scinai Immunotherapeutics positions in Q1 2017 and 1 closed out, a net change of +2 holders.
  • The largest Scinai Immunotherapeutics buyer in Q1 2017 was Citadel Advisors, an estimated $160K added.
  • The largest Scinai Immunotherapeutics seller in Q1 2017 was Bank of Montreal, an estimated $44K sold.

Based on aggregated 13F filings for Q1 2017.